A Natural Ally Against Hypertension: Nisatol® Shows Promising Results in Real-World Study

Nisatol®, a nutraceutical derived from Nigella sativa seed oil standardized to 10% thymoquinone, offers a novel complementary strategy for managing suboptimal blood pressure, particularly in patients with limited response to pharmacological therapy. A recent 2025 multicenter observational pilot study evaluated its effects in a specific population already undergoing standard treatment. Preliminary findings revealed promising trends.

The Ongoing Challenge of Hypertension: Exploring Complementary Strategies with Nisatol®

Controlling blood pressure remains one of the greatest challenges in cardiovascular care, largely due to hypertension’s silent nature and its significant impact on cardiovascular disease development. When lifestyle modifications fall short, pharmacological therapies become necessary—but their effectiveness is often limited by side effects and poor adherence.

In this context, Nisatol®, a nutraceutical based on Nigella sativa seed oil standardized to contain 10% thymoquinone—the highest concentration available on the market—offers a promising complementary strategy. Thymoquinone is well-studied for its ability to modulate blood pressure and other cardiometabolic parameters, making it a key ally in achieving better clinical outcomes.

The Latest Clinical Evidence: 2025 Pilot Study

A new clinical study published in Nutrients (March 2025) evaluated the cardiometabolic effects of Nisatol® in postmenopausal women with suboptimal hypertension, already under standard antihypertensive therapy. This multicenter, prospective observational pilot study enrolled 52 women divided into three groups:

  • Group A: 16 women received 400 mg/day of Nigella sativa (1 soft gel capsule/day of Nisatol®)
  • Group B: 16 women received 800 mg/day of Nigella sativa (2 soft gel capsules/day of Nisatol®)
  • Control group: 20 women continued their pharmacological treatment without the nutraceutical

All participants maintained their prescribed antihypertensive regimens throughout the 8-week study. Cardiometabolic parameters were assessed at baseline (T0), 4 weeks (T4), and 8 weeks (T8).

Clinical outcomes: time- and dose-dependent efficacy on blood pressure

After just 4 weeks, the Nisatol®-treated groups showed a significant reduction in heart rate, along with a trend toward lower systolic and diastolic blood pressure. These improvements were more pronounced in the group that received 2 soft gel capsules of Nisatol®, and by week 8, the following reductions were observed:

  • –16 mmHg systolic blood pressure
  • –6 mmHg diastolic blood pressure


The association between the higher dose (800 mg/day) and the most consistent, clinically meaningful improvements confirms a clear dose-response relationship.

Broader cardiometabolic benefits: beyond blood pressure

Although the study focused primarily on hypertension management, additional benefits were observed in lipid profile and climacteric symptoms—particularly relevant in the population studied, which consisted of postmenopausal women:

  • Significant reduction in LDL cholesterol (–15% with 2 soft gel capsules at 8 weeks)
  • Improvement in Greene Climacteric Scale scores (–61% with 2 soft gel capsules at 8 weeks), reflecting better quality of life and reduced menopausal symptoms


These findings indicate that Nisatol® may offer broader metabolic benefits and contribute to improved quality of life, positioning it as a comprehensive option for cardiometabolic support in postmenopausal patients.

Conclusion

Clinically tested, well-tolerated, and naturally derived, Nisatol® demonstrates compelling efficacy as an add-on therapy in individuals with suboptimal blood pressure control. With a unique high-thymoquinone formulation and a growing body of supporting data, it represents a promising complementary approach to modern cardiovascular care.